Literature DB >> 23328798

Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study.

J F Arevalo, M A Serrano, L Wu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23328798      PMCID： PMC3626005          DOI： 10.1038/eye.2012.301

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  3 in total

1.  intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.

Authors:  Lihteh Wu; Erick Hernandez-Bogantes; José A Roca; J Fernando Arevalo; Karen Barraza; Andres F Lasave
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

2.  Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab.

Authors:  Petros P Sfikakis; Nikos Markomichelakis; George P Theodossiadis; Vlassis Grigoropoulos; Nikos Katsilambros; Panayiotis G Theodossiadis
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

3.  Intravitreal adalimumab for refractory uveitis-related macular edema.

Authors:  Sofia Androudi; Evangelia Tsironi; Christos Kalogeropoulos; Athina Theodoridou; Periklis Brazitikos
Journal:  Ophthalmology       Date:  2010-04-08       Impact factor: 12.079
  3 in total
  3 in total

Review 1.  Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders.

Authors:  Isabel Pascual-Camps; Pablo Hernández-Martínez; Laura Monje-Fernández; Rosa Dolz-Marco; Roberto Gallego-Pinazo; Lihteh Wu; J Fernando Arévalo; Manuel Díaz-Llopis
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-10-15

Review 2.  A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.

Authors:  Nasiq Hasan; Rohan Chawla; Nawazish Shaikh; Sindhuja Kandasamy; Shorya Vardhan Azad; M Dheepak Sundar
Journal:  Ther Adv Ophthalmol       Date:  2022-05-18

3.  Blockade of Tumor Necrosis Factor-Alpha: A Role for Adalimumab in Neovascular Age-Related Macular Degeneration Refractory to Anti-Angiogenesis Therapy?

Authors:  Beatriz Fernández-Vega; Álvaro Fernández-Vega; Carlos Mario Rangel; Javier Nicieza; Eva Villota-Deleu; José A Vega; Ronald M Sanchez-Avila
Journal:  Case Rep Ophthalmol       Date:  2016-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.